BioSpace News Archive

Cumulus Neuroscience presented interim data from their real-world feasibility study CNS-101 at the Alzheimer’s Association International Conference 2023 in Amsterdam, Netherlands.

Caeregen Therapeutics announced today that it has been awarded a $1.4 million Phase 2 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) and National Eye Institute (NEI) to advance the development of CTR-107 (Noregen™), a novel regenerative therapeutic for the treatment of retinal-related vision loss due to a wide range of inherited and age-related diseases.

Laxxon Medical, a leading 3D screen printing pharma-technology company, announced their strategic partnership with CU Innovations at the University of Colorado Anschutz Medical Campus.

BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System, announced receipt of the grand prize award in the 2023 Merck Advance Biotech Grant Program.

Affluent Medical (Euronext Paris: FR0013333077 – AFME), a French clinical-stage MedTech company specialized in the international development and commercialization of innovative medical prostheses to treat mitral heart valve pathology and urinary incontinence, today announced the appointments of Christophe de Vregille as Chief Financial Officer (CFO) and Benjamin Renault as Chief Development Officer (CDO).

Capital Rx, the health technology company changing the way prescription drugs are priced and patients are cared for, and type 2 diabetes reversal leader Virta Health have partnered to introduce Rx Reverse.

Adolore Biotherapeutics, a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, announced the presentation of preclinical data for its innovative CA8* gene therapy, rdHSV-CA8*, at the 2023 ASPN Annual Conference, held July 13-16, 2023 in Miami, FL.

Kick-off meetings have taken place in all academic sites that will be participating in the pivotal validation plan towards regulatory approvals of iBiopsy® LCS CADe/CADx SaMD.

Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, announced an expanded collaboration with Sanofi.

Median Technologies announced that Fredrik Brag, CEO and Founder of Median Technologies, will provide a company update on July 20, 2023 during two webcasts.